Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort

NCT ID: NCT06511297

Last Updated: 2026-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

650 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-05

Study Completion Date

2036-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or without obesity.

The main question is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ongoing increase in human life expectancy is steadily reshaping the demographic landscape, leading to a higher proportion of older adults, many of whom suffer from multiple health conditions. These unprecedented demographic shifts come at a significant socioeconomic cost, as aging stands as the primary risk factor for chronic disabilities and disorders such as cardiovascular diseases, dementia, type 2 diabetes, obesity, steatotic liver disease and infections. Consequently, promoting healthy aging emerges as one of the most pressing societal challenges in the foreseeable future, underscoring the urgent need for clinically validated strategies to extend the disease-free phase of life, known as health span.

The Pro-MetAGE prospective cohort as part of the clinical program of the MetAGE Cluster of Excellence (Austrian Science Fund # 10.55776/COE14) will focus on understanding the metabolic dysregulation associated with aging in a metabolic at-risk population. Metabolic control, which encompasses various aspects and is influenced by numerous aging indicators, might be the primary driver of age-related diseases. For instance, contemporary markers of biological age, such as epigenetic clocks based on DNA methylation and cellular senescence markers, correlate more closely with metabolic processes like nutrient sensing and mitochondrial function rather than genome stability or telomere length.

Aging entails a gradual deterioration of several fundamental metabolic processes, including lipostasis (fat metabolism), proteostasis (protein homeostasis), polyamine metabolism, and mitochondrial function. These intracellular changes are compounded by alterations in intercellular and interorgan communication, affecting brain-organ interactions and immune function. The decline in these crucial processes can disrupt the regulatory mechanisms of metabolic control in a manner influenced by sex and gender. Consequently, the loss of metabolic control may exacerbate other aging processes, setting off a detrimental cycle of accelerated aging.

Disruption in metabolic regulation caused by calorie-rich diets, disturbed circadian rhythms, or sedentary lifestyle can lead to a diverse set of health issues known collectively as metabolic syndrome. These medical conditions, including obesity, high blood pressure, elevated lipid levels, insulin resistance, and high blood sugar, contribute to the development of prevalent age-related diseases such as cardiovascular disease, type 2 diabetes, retinal degeneration and metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease, affecting millions of older individuals globally. Additionally, there exists a significant link between metabolic imbalance and dysfunction in the immune system, resulting in heightened susceptibility to infections, diminished response to vaccinations, and various neuropsychiatric disorders, especially depression. Hence, understanding the mechanisms underlying metabolic dysregulation holds immense importance in devising preventive measures against some of the most debilitating age-related ailments.

The proposed research project aims to prospectively identify and validate aging biomarkers in relation to age- and sex-related cardiometabolic changes in young and old individuals, who are lean or obese/overweight (i.e. a metabolic at-risk population) with regard to lipostasis, proteostasis, polyamine metabolism, mitochondrial function, inflammation and cellular senescence. The goal is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Aging Aging Problems Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lean, young adults

comprehensive metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Overweight, young adults

comprehensive metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Lean, older adults

comprehensive metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Overweight, older adults

comprehensive metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Nonagenerians Age ≥ 90

Note: Nonagenarian Group will only be phenotyped once

comprehensive metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

comprehensive metabolic phenotyping

The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 1 - Lean, young adults (n = 150)

* Age 18 - 35 years
* Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)

Group 2 - Overweight, young adults (n = 150)

* Age 18 - 35 years
* BMI ≥ 28kg/m2 (≥ 12 months)

Group 3 - Lean, older adults (n = 150)

* Age ≥ 60 years
* BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years)

Group 4 - Overweight, older adults (n = 150)

* Age ≥ 60 years
* BMI ≥ 28 kg/m2 (≥ 3 years)
* Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II).
* Subgroup B (n=75): without pre-existent cardiovascular disease

Group 5 - Nonagenerians Age ≥ 90 (n = 50)

* Age ≥ 90 years
* BMI ≥ 18.5 kg/m2 (≥ 3 years)

Exclusion Criteria

Group 1 - Lean, young adults (n = 150)

* Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Clinically significant metabolic or endocrine disorders
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
* Metal implants that prohibit 3T MRI
* Pregnancy or breastfeeding

Group 2 - Overweight, young adults (n = 150)

* Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion)
* Clinically significant metabolic or endocrine disorders
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
* Metal implants that prohibit 3T MRI
* Pregnancy or breastfeeding

Group 3 - Lean, older adults (n = 150)

* Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Diabetes, overt hypo/hyperthyroidism
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Metal implants that prohibit 3T MRI
* Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) \< 35% or NYHA Class III-IV)
* No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
* Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.

Group 4 - Overweight, older adults (n = 150)

* Special diets (i.e. ketogenic diet and time-restricted eating)
* Diabetes, overt hypo/hyperthyroidism
* Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion)
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Metal implants that prohibit 3T MRI
* No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
* Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.

Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50)

* Claustrophobia
* Clinically significant cognitive impairment compromising study adherence
* Metal implants that prohibit 3T MRI
* Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Graz

OTHER

Sponsor Role collaborator

University of Graz

OTHER

Sponsor Role collaborator

Thomas Scherer

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thomas Scherer

Assoc. Prof. Dr. med.

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Graz

Graz, Styria, Austria

Site Status RECRUITING

Medical University of Vienna

Vienna, Vienna, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Pieber, MD, Prof.

Role: primary

+43 316 385 82383

Thomas Scherer, MD

Role: primary

+43 1 40400 43121

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1632/2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cohort Study in Fujian Province
NCT06102187 RECRUITING